The Royal Glamorgan Hospital (Welsh: Ysbyty Brenhinol Morgannwg), is a District General Hospital in Ynysmaerdy, Talbot Green, Rhondda Cynon Taf, South Wales. It is managed by the Cwm Taf Morgannwg University Health Board.
Cow's milk allergy (CMA) remains one of the most common food allergies in infancy, requiring the avoidance of cow's milk and its derivatives. Breast milk is the best source of nutrition for infants. For those infants with CMA whose mothers are unable to breastfeed or choose not to, extensively hydrolysed formulas (eHFs) are widely recommended as first-line milk substitutes, whereas hydrolysed rice formulas (HRFs) are increasingly recognised as a viable alternative. This concept paper provides a healthcare professional (HCP) perspective on HRF, drawing on expert consensus from two meetings convened in 2025. Discussions noted the long history of safe and effective HRF use in Europe, its nutritional adequacy, and the evolving international guidelines supporting HRF as an alternative first-line option. A key meeting outcome was the development of a practical decision tree to help UK clinicians decide when HRF should be the preferred choice. Key considerations for its use in non-breastfed infants include the following: parental/caregiver stress related to persistent symptoms; ongoing symptoms despite multiple interventions; cultural and lifestyle choices; religious dietary requirements; and specialists' recommendations. Secondary considerations highlighted by HCPs include the following: proven reactions whilst infants are breast-milk-fed together with parental request for formula; faltering growth; multiple symptoms; taste acceptance (older infants); and parental preference based on experience. The role of functional components, such as prebiotics and human milk oligosaccharides (HMOs), was noted in regard to the emerging evidence of benefits to the microbiome and immune development. The experts emphasised the importance of engaging HCPs across all levels of CMA care and addressing challenges in translating current guidance into treatment practice. It was concluded that, overall, HRF represents a nutritionally complete, plant-based alternative that has been shown to be well tolerated (taste, symptoms) in clinical studies. It can be used to broaden therapeutic options for infants with CMA in the UK who are not exclusively fed breast milk.
Background Approximately 55 900 women are diagnosed with breast cancer in the UK each year, and around one in five develop lymphoedema following treatment. Breast, trunk and arm lymphoedema arise from disruption to shared lymphatic drainage pathways during axillary surgery and radiotherapy, yet the condition remains under-recognised and under-referred in many post-treatment care pathways and women can struggle to find appropriate bras to support their care needs. Aims This article explores why and where lymphoedema develops after breast cancer treatment, presents the patient experience of living with breast and trunk lymphoedema, and evaluates the clinical evidence for 3D micro-massage compression technology — specifically the Solidea® Silver Wave Skin Bra — as an adjunct to standard lymphoedema management. Methods This article combines a narrative review of current evidence on breast and trunk lymphoedema with first-person patient testimony and findings from a pilot audit of 21 women with breast and/or trunk lymphoedema following breast cancer treatment. Audit outcome measures included the clinician-completed Breast Symptom Assessment Score, the wearer-completed Self-Report Symptom Rating Scale, structured wearer feedback and qualitative telephone follow up at approximately 26 days and 11 weeks. Findings Women sometimes report a delay between symptom onset and receiving support, alongside difficulty sourcing an appropriate, comfortable bra; these issues are compounded further for those wearing a breast prosthesis. In the pilot audit, mean Breast Symptom Assessment Score reduced by 60% (from 5.8 to 2.3) over approximately 26 days, with moderate-to-severe swelling falling from 70% to 15%, breast hardness from 90% to 65%, and night-time discomfort from 85% to 45%. All 20 completing participants showed improvement, with 100% rating comfort as excellent or good; the lowest-rated domain in self-reported symptoms scales was degree of support, particularly among women with cup sizes above D. Conclusions Breast and trunk lymphoedema is common, chronic and profoundly life-limiting, with psychological and social impact that compounds the burden of breast cancer treatment. Proactive risk information, early referral and holistic support are essential. Implication for practice 3D micro-massage compression may support self-management alongside complete decongestive therapy, but clinicians should consider patient suitability and the current evidence gaps in larger-breasted women and other garment formats.